A new phase 2 clinical trial suggests that a chemotherapy-free, minimal residual disease (MRD)–driven treatment strategy may offer durable remissions and the possibility of time-limited therapy for ...

Directed evolution,' which induces mutations in genetic material to create useful functions, is considered a core technology ...

Key milestone achieved as Company advances clinical program to full approval trial of ateganosine sequenced with a checkpoint ...

Targeted therapies and immunotherapies are increasingly offering viable alternatives to the chemotherapies that have stood for decades as a mainstay of treatment for individuals living with blood ...

Tukysa added to Herceptin and Perjeta improved progression-free survival versus placebo in HER2-positive metastatic breast ...

Pfizer has rolled out detailed trial data suggesting Tukysa could be part of a new first-line treatment to delay the progression of HER2-positive breast cancer. | Pfizer has rolled out detailed trial ...

Researchers identified trimethylamine (TMA) as a gut microbe–derived metabolite that directly inhibits IRAK4 to reduce ...

Tucatinib addition to trastuzumab and pertuzumab significantly improved PFS in HER2-positive metastatic breast cancer, with a median PFS of 24.9 months versus 16.3 months with placebo. The PFS benefit ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

The trial results support Tukysa-Herceptin-Perjeta as yet another option for breast cancer patients in the frontline ...

The addition of tucatinib to first-line trastuzumab plus pertuzumab delayed disease progression among a cohort of women with ...

The bacterium that causes TB can hide in liver cells called hepatocytes, and reprogram their metabolism for its own benefit.